Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (102)
December 8, 2008
-
Maurer's Healthcare Insight (101)
December 1, 2008
-
Maurer's Healthcare Insight (100)
October 27, 2008
-
Maurer's Healthcare Insight (99)
September 29, 2008
-
Maurer's Healthcare Insight (98)
August 25, 2008
-
Maurer's Healthcare Insight (97)
July 28, 2008
-
Maurer's Healthcare Insight (96)
June 23, 2008
-
Maurer's Healthcare Insight (95)
May 19, 2008
-
Maurer's Healthcare Insight (94)
March 10, 2008
-
Maurer's Healthcare Insight (93)
February 18, 2008
-
Maurer's Healthcare Insight (92)
January 21, 2008
-
Maurer's Healthcare Insight (91)
December 24, 2007
-
Maurer's Healthcare Insight (90)
November 5, 2007
-
Maurer's Healthcare Insight (89)
October 8, 2007
-
Maurer's Healthcare Insight (88)
August 6, 2007
-
Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer
June 4, 2007
-
Maurer's Healthcare Insight (86)
May 28, 2007
-
Maurer's Healthcare Insight (85)
April 16, 2007
-
Maurer's Healthcare Insight (84)
March 26, 2007
-
Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer
March 12, 2007
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…